WO2006123781A1 - 微粒子を用いた微生物及び核酸の回収方法ならびにそれらに用いるキット - Google Patents
微粒子を用いた微生物及び核酸の回収方法ならびにそれらに用いるキット Download PDFInfo
- Publication number
- WO2006123781A1 WO2006123781A1 PCT/JP2006/310043 JP2006310043W WO2006123781A1 WO 2006123781 A1 WO2006123781 A1 WO 2006123781A1 JP 2006310043 W JP2006310043 W JP 2006310043W WO 2006123781 A1 WO2006123781 A1 WO 2006123781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microorganism
- nucleic acid
- fine particles
- recovery
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24251—Methods of production or purification of viral material
Definitions
- the present invention relates to a method for recovering microorganisms and nucleic acids using fine particles, and a kit used for them.
- Nucleic acid analysis plays an important role in diagnosing infectious diseases and genetic diseases at the genetic level in the medical field.
- the analysis is not limited to the medical field, such as agriculture or food. It is applied and used in various fields.
- nucleic acid For analysis of nucleic acid, it is necessary to recover the nucleic acid from a sample (eg, bacterial cell culture medium, urine, blood, etc.).
- a sample eg, bacterial cell culture medium, urine, blood, etc.
- the method of this document is based on the knowledge that the bacterial cells can be magnetically separated together with the magnetic particles because the bacterial cells bind nonspecifically to the magnetic particles under acidic conditions. More specifically, first, magnetic particles and a bacterial cell culture solution are mixed under acidic conditions to immobilize the bacterial cells on the magnetic particles, and then a magnetic field is applied to recover the magnetic particles by liquid force. Next, the magnetic particles are suspended to separate the magnetic particle force cells, and then the cells are dissolved to elute DNA. Then, the target DNA is obtained by fixing the eluted DNA to magnetic particles.
- cells are immobilized on a solid support such as magnetic silica particles, then the nucleic acid of the cells is eluted, and the nucleic acid is bound to the solid support to form a nucleic acid.
- a method of recovering see, for example, Patent Document 2.
- Patent Document 1 Japanese Patent Publication No. 2003-521228
- Patent Document 2 Japanese Translation of Special Publication 2002-507116
- the present invention has been made in view of such circumstances, and an object thereof is to provide a method for recovering microorganisms and nucleic acids that is simple and has a high recovery rate.
- the microorganism recovery method of the present invention is a microorganism recovery method using microparticles, and includes a microorganism adsorption step of bringing microparticles into contact with a sample and adsorbing the microbes in the sample to the microparticles,
- the fine particles have a particle size of 6 ⁇ m or less and a specific surface area of 50 m 2 Zg or less.
- the nucleic acid recovery method of the present invention includes a microorganism adsorption step for adsorbing microorganisms in a sample to microparticles, and a nucleic acid elution step for eluting nucleic acids from the microorganisms adsorbed to the microparticles, and the microorganism adsorption
- the process is characterized in that it is the microorganism recovery method of the present invention.
- the inventors of the present invention have made extensive studies to improve the recovery rate of microorganisms and nucleic acids from a sample.
- the knowledge that the particle size and specific surface area of the fine particles used have a great influence on the recovery rate of microorganisms was obtained, and as a result of further research, the present invention It came. That is, in order to increase the recovery rate of microorganisms, it is usually considered to use fine particles having a large specific surface area to increase the total surface area of the fine particles.
- fine particles with a large specific surface area were used, it was found that even though the total surface area was large, microorganisms could not be sufficiently adsorbed. This is probably due to the following reasons.
- the fine particles having a large specific surface area for example, those having many pores on the surface are conceivable, but in this case, since the contact area between the microorganisms and the fine particles is small, it is considered that the microorganisms cannot be sufficiently adsorbed. It is done.
- the microparticles having a particle diameter of 6 ⁇ m or less and a specific surface area of 5 Om 2 Zg or less used in the microorganism recovery method of the present invention are used, for example, the contact area between the microorganisms and the microparticles is increased. It is thought that the amount of microorganisms adsorbed per particle could be increased.
- the recovery rate of microorganisms can be improved, and a complicated process such as centrifugation is not required, so that simple recovery is possible. Further, since the recovery rate is improved by using the fine particles as described above, for example, it is possible to recover the microorganisms with a high recovery rate even if the amount of fine particles is smaller than that of the conventional one.
- the nucleic acid recovery method of the present invention recovers microorganisms by the microorganism recovery method of the present invention, so that microorganisms can be recovered at a high recovery rate, and nucleic acids are extracted from microorganisms recovered at such a high recovery rate. Nucleic acids can be efficiently recovered.
- FIG. 1 is a graph showing the results of real-time PCR measurement in Example 7 of the present invention.
- FIG. 2 is a graph showing the results of real-time PCR measurement in Example 8-1 and Comparative Example 6-1 of the present invention.
- FIG. 3 is a graph showing the results of real-time PCR measurement in Example 8-1 and Comparative Example 6-2 of the present invention.
- FIG. 4 is a graph showing measurement results of real-time PCR in Example 9 and Comparative Example 7 of the present invention.
- FIG. 5 is a graph showing measurement results of real-time PCR in Example 10 and Comparative Example 8 of the present invention.
- FIG. 6 is a graph showing the recovery rates in Examples 13-1 and 13-2 and Comparative Example 11 of the present invention.
- FIG. 7 is a graph showing the recovery rates in Example 13-3 and Comparative Example 12 of the present invention.
- FIG. 8 is a graph showing the recovery rates in Examples 14-1 and 14-2 and Comparative Example 13 of the present invention.
- FIG. 9 shows the recoveries in Examples 14-3 and 14-4 of the present invention and Comparative Example 14. It is a graph which shows.
- the upper limit of the particle diameter of the fine particles is 6 ⁇ m or less, preferably 4 ⁇ m or less, more preferably 2 ⁇ m or less, and even more preferably. Is 1 ⁇ m or less, particularly preferably 0 or less.
- the lower limit value is not particularly limited, but is preferably, for example, 0 or more. Microparticles having such a particle size can recover microorganisms at a high recovery rate as described above. In addition, even with a smaller amount of fine particles than in the past, microorganisms can be recovered at a high recovery rate, which is extremely advantageous in terms of cost.
- the particle diameter is a line connecting a certain point on the outer periphery of the fine particle and other points, and is the length of the longest line.
- the particle diameter is measured using a scanning electron microscope (SEM). It can be obtained by directly observing fine particles.
- SEM scanning electron microscope
- the particle diameter of 50% or more of the fine particles is within the above range, and preferably 70% or more.
- the upper limit of the specific surface area of the particle diameter is 50 m 2 Zg or less, preferably
- the lower limit of the specific surface area is not particularly limited, but is preferably lm 2 / g or more.
- the specific surface area can be calculated by, for example, the BET (nitrogen adsorption) method standardized by JISK1150 “Silica gel test method”.
- the specific surface area of 50% or more of the fine particles is within the above range, and preferably 70% or more.
- the particle diameter and specific surface area of the fine particles may be determined according to, for example, the type of microorganisms to be collected, which will be described later.
- the collection target is bacterial cells
- a particle diameter of 0.1 to 6 / ⁇ ⁇ a specific surface area of 1 to 50 m 2 Zg is more preferable, and a particle diameter of 0.1 to 2 m, a specific surface area is preferable.
- the collection target is a virus
- a particle diameter of 0.1 to 6 / ⁇ ⁇ a specific surface area of 1 to 50 m 2 / g is preferred, and a particle diameter of 0.1 to 2 m, a specific surface area of l ⁇ 30m is a 2 / g.
- the fine particles include, for example, fine particles having a hydroxyl group or the like on the surface thereof, but the surface has a silica compound, or a resin having a hydroxyl group such as poly (ethlene, alkyl-OH, acrylate) or polyethylene glycol. Fine particles containing etc. are preferred. With such fine particles, for example, it becomes easier to adsorb microorganisms, so that the recovery rate can be further improved.
- the fine particles may be fine particles having magnetism! /, And may be fine particles having no magnetism. For example, it is easier to separate the fine particles from the liquid. Therefore, magnetic particles are preferable.
- the magnetic particles do not have to be magnetic as a whole as long as some of the fine particles have magnetism. That is, examples of the magnetic particles include magnetic particles obtained by coating at least part of the surface of particles made of a magnetic material with a nonmagnetic material, and magnetic particles obtained by kneading and granulating a magnetic material and a nonmagnetic material. Particles and the like. As the fine particles, commercially available fine particles may be used.
- the magnetic material is not particularly limited as long as it has magnetism, and examples thereof include metals such as iron, chromium and nickel, metal oxides such as iron oxide and chromium oxide, and magnetic alloys. It is done.
- the acid pig iron include Fe 2 O (magnetite), Fe 2 O (maghemite), r
- Fe 2 O (r-type 322 iron) and the like can be mentioned.
- the nonmagnetic material include silica compounds.
- silica compound examples include glass, celite diatomaceous earth, silica polymer, magnesium silicate, silicone nitrogen compound (eg, SiN), aluminum silicate, silicon dioxide and silicon dioxide.
- silica compound examples include glass, celite diatomaceous earth, silica polymer, magnesium silicate, silicone nitrogen compound (eg, SiN), aluminum silicate, silicon dioxide and silicon dioxide.
- silica compound examples include glass, celite diatomaceous earth, silica polymer, magnesium silicate, silicone nitrogen compound (eg, SiN), aluminum silicate, silicon dioxide and silicon dioxide.
- silicone nitrogen compound eg, SiN
- Examples of the coconut resin having a hydroxyl group include poly (ethlene, alkyl-OH, acrylate), polyethylene glycol, and the like.
- the fine particles are preferably magnetic silica particles containing a magnetic material such as a magnetic metal or a magnetic metal oxide, and more preferably magnetic silica particles obtained by coating the magnetic material with a silica compound.
- examples of the non-magnetic! / Fine particles include particles made of a non-magnetic material, and the non-magnetic material is the same as described above.
- microparticles in the present invention are excellent in the recovery rate as described above, even if the amount of microparticles is smaller than that in the past, microorganisms can be recovered with excellent efficiency. In this way, if the amount of fine particles used can be reduced, for example, it is possible to sufficiently separate liquid force fine particles from which microorganisms have been collected. In other words, as described above, in the past, it was necessary to increase the amount of fine particles used to improve the recovery rate. Liquid force from which nucleic acid was recovered It was difficult to sufficiently separate the fine particles. On the other hand, in the present invention, since the amount of use can be reduced by using the above-mentioned fine particles, it is possible to sufficiently separate the recovered fine particles of liquid force.
- the particles may remain in the recovery solution. If fine particles remain in this way, for example, in nucleic acid amplification by a PCR (Polymerase chain reaction) method, the remaining fine particles may become an inhibitor of the reaction, and the nucleic acid may not be sufficiently amplified.
- a label attached to a nucleic acid is measured and detected by an optical method, measurement errors may occur due to residual fine particles in the recovered solution.
- the microorganisms and the fine particles are sufficiently separated as described above, for example, the above-described problem due to the remaining fine particles can be avoided. For this reason, for example, a decrease in PCR amplification efficiency and a decrease in analysis accuracy can be suppressed.
- fine particles smaller than conventional particles are used. Can be recovered. Further, since the particle size is small in this way, it is possible to add more fine particles to the sample than before, and this can further improve the recovery rate.
- the microorganism includes, for example, microbial cells, viruses and cells.
- the cells include, but are not limited to, bacteria and fungi. Examples include staphylococci, streptococci, Escherichia coli, Pseudomonas aeruginosa, and plague.
- the virus include ⁇ phage, immunodeficiency virus, leukocyte virus, Japanese encephalitis virus, hepatitis C virus (HBV), hepatitis C virus (HCV), adult T cell leukemia virus (ATLV), human immunity Infectious virus (HIV) and Ebola virus.
- the cells include leukocytes, epithelial cells, mucosal cells, somatic cells, and other animal and plant cells.
- the microorganism recovery method of the present invention is a method for recovering microorganisms using fine particles.
- the microorganism adsorption step of bringing microparticles into contact with a sample and adsorbing the microorganisms in the sample to the microparticles.
- the fine particles have a particle size of 6 m or less and a specific surface area of 50 m 2 / g or less.
- a microorganism recovery liquid containing fine particles is prepared in advance, and in the microorganism adsorption step, the microorganism recovery liquid and the sample are brought into contact with each other to adsorb the microorganisms in the sample to the microparticles.
- the content of the fine particles in the microorganism collection liquid is not particularly limited, and can be determined based on, for example, the type and amount of microorganisms to be collected, the particle diameter of the fine particles to be used, the specific surface area, and the like.
- the sample is urine, blood, or the like, for example, it is preferable to use 0.1 to LOmg fine particles with respect to 100 L of the sample, and more preferably 1 to 5 mg.
- the microorganism recovery solution refers to a reagent used for adsorbing microorganisms to fine particles.
- the microorganism recovery liquid is preferably an acidic liquid or a neutral liquid, for example.
- the acidic solution preferably has a pH of, for example, 2 to 3, and examples thereof include a formate buffer solution, an acetate buffer solution, a citrate buffer solution, and a glycine hydrochloride buffer solution.
- the neutral solution is a buffer solution, for example, Tris-HC1 and the like can be mentioned.
- the neutral solution preferably contains a salt such as Mg salt, Na salt, Ca salt and K salt, more preferably Mg salt. These salts may be used alone or in combination of two or more. By using a neutral solution containing such a salt, a high recovery rate can be realized even with a smaller amount of fine particles.
- Specific examples of the salt include MgCl, NaCl, Ca
- the microorganism recovery solution contains, for example, a protein denaturant.
- a protein denaturant for example, a non-surfactant denaturant is preferable.
- the non-surfactant-based modifier include heavy metal salts, organic solvents, urea, and the like, and specific examples include guam salt, ethanol and vinegar. Acid is preferred.
- microparticles adsorbed with microorganisms can be collected using, for example, a magnet, as described later.
- the microbe adsorbed on the microparticles can be separated from the microparticles, for example, by suspending the microparticles in physiological saline or a surfactant having an appropriate concentration.
- the nucleic acid recovery method of the present invention includes a microorganism adsorption step in which microorganisms in a sample are adsorbed to fine particles by the microorganism recovery method of the present invention, and a microorganism cartridge adsorbed on the fine particles. And a nucleic acid elution step for eluting the nucleic acid.
- the fine particles are brought into contact with a nucleic acid extraction reagent to elute the nucleic acids from the microorganisms adsorbed on the fine particles.
- the nucleic acid extraction reagent can be determined according to the type of microorganism to be collected, and is not particularly limited.
- polyoxyethylene-p-tert-butyl ether Triton-based surfactant, etc.
- polyoxy Examples thereof include surfactants such as ethylene sorbitan alkyl esters (Tween surfactants, etc.) and sodium dodecyl sulfate (SDS), ethylene diamine tetraacetic acid (EDTA), and the like.
- Triton surfactant examples include trade name TritonX-100, and specific examples of the Tween surfactant include trade name Tween20.
- the solvent for the nucleic acid extraction reagent is not particularly limited, and examples thereof include a buffer solution such as Tris-HCl.
- the nucleic acid recovery method of the present invention may further include a liquid separation step.
- the microorganism adsorption step the microorganism collection liquid containing fine particles is contacted with a sample containing microorganisms to adsorb the microorganisms to the fine particles, and then in the liquid separation step, the fine particles and liquid (for example, And the nucleic acid elution step.
- the microorganism recovery liquid is as described above.
- nucleic acid recovery method of the present invention a method for recovering nucleic acid from microorganisms adsorbed on fine particles will be described.
- the fine particles are magnetic particles
- it can be performed as follows. First, in the liquid separation process, magnetic force is applied by an external force magnet or the like of the container to attach magnetic particles to the inner surface of the container, and in this state, the container force liquid is removed and the microorganisms are adsorbed. Collect the magnetic particles. According to this method, the sample force which does not need to be centrifuged to separate unnecessary components (for example, liquid components) and necessary components (for example, solid components such as magnetic particles) can be recovered. Can be simplified.
- the magnetic particles are dispersed in a nucleic acid extraction reagent and heated during the nucleic acid elution step.
- the heating temperature and heating time are not particularly limited, and can be set according to, for example, the type and amount of microorganisms and nucleic acid extraction reagents to be collected.
- the heating temperature is 80 to 100 ° C.
- the heating time is Is preferably 1 to 10 minutes.
- nucleic acid extraction reagent containing nucleic acid is collected from the container. Nucleic acids can be recovered. According to this method, it is possible to simplify the operation of recovering the nucleic acid that does not need to be centrifuged to separate unnecessary components (for example, magnetic particles) and necessary components (nucleic acid extraction reagent containing nucleic acids).
- the fine particles are not magnetic particles, for example, the following can be carried out.
- the liquid separation step for example, the fine particles are naturally allowed to settle by their own weight to separate the fine particles from the liquid.
- the nucleic acid elution step is performed in the same manner as in the case of the magnetic particles, and after elution of the nucleic acid, for example, after the natural precipitation of the microparticles by the dead weight of the microparticles, The nucleic acid can be recovered by recovering the supernatant.
- the microorganism collection kit of the present invention is a microorganism collection kit used in the microorganism collection method of the present invention, and has a particle diameter of 6 ⁇ m or less and a specific surface area thereof.
- microorganisms can be recovered at a high recovery rate by using such fine particles.
- a high recovery rate can be realized, which is extremely advantageous in terms of cost.
- the fine particles those similar to the method for recovering microorganisms of the present invention can be used, and among them, magnetic silica particles are preferable.
- the method for determining the particle diameter and specific surface area is as described above.
- the microorganism collection kit of the present invention further includes a microorganism collection solution containing the fine particles.
- the microorganism recovery solution is used for the microorganism recovery method of the present invention. can give.
- the nucleic acid recovery kit of the present invention is a nucleic acid recovery kit used in the nucleic acid recovery method of the present invention, and has a particle size of 6 ⁇ m or less and a specific surface area of 50 m 2.
- nucleic acids can be recovered at a high recovery rate by using such fine particles.
- a high recovery rate can be realized, which is extremely advantageous in terms of cost.
- the fine particles can be the same as those used in the method for recovering microorganisms of the present invention.
- magnetic silica particles coated with a silica compound are preferable.
- the nucleic acid extraction reagent used in the nucleic acid recovery method of the present invention can be used, and the method for determining the particle size and specific surface area is as described above.
- the nucleic acid recovery kit of the present invention preferably further includes a microorganism recovery solution containing the fine particles.
- a microorganism recovery solution containing the fine particles examples include those used in the microorganism collection method of the present invention.
- the particle diameter is a line connecting a point with the outer periphery and the other point, and is the length of the longest line, determined using an electron microscope, and the ratio The surface area was determined based on the BET (nitrogen adsorption) method standardized by JISK1150 “Silica gel test method”.
- This example is an example in which bacterial cells (gonococci) were collected using acidic silica particles under acidic conditions and the bacterial cell strength nucleic acid was collected.
- a magnetic silica particle-containing liquid 200 mgZ mL was prepared using each magnetic silica particle shown in Table 1 below.
- Example 11 and 12 the surface modification of the fine particles of Examples 11 and 12 and Comparative Example 1 is SiO.
- the fine particles of Example 1-3 are trade name MagExtmctor (R) — Genome
- Magnetic silica particles included in the gene extraction kit included in the gene extraction kit.
- Neisseria gonorrhoeae colonies cultured on chocolate agar medium are collected and suspended in physiological saline so that the absorbance (OD) at a wavelength of 530 nm is 0.18.
- a bacterial cell solution was prepared.
- the bacterial cell solution is diluted 100-fold with physiological saline, 100 ⁇ L of the diluted bacterial cell solution and 120 L of the microorganism recovery solution are mixed, and pipetting 10 times to dispose the bacterial cells on the magnetic silica particles.
- the magnetic silica particles were collected with a magnet and the supernatant was removed.
- 200 L of 10 mM glycine-HCl (pH 3) was added and pipetted 10 times, and the magnetic silica particles were washed by removing the supernatant in the same manner as described above. This washing operation was repeated three times. Thus, impurities were removed, and the bacterial cells in the bacterial cell liquid were recovered while adsorbed on the magnetic silica particles.
- Nucleic acid was extracted from the collected magnetic silica particles by pipetting 10 times with 100 ⁇ L of the nucleic acid extraction reagent, heating at 95 ° C. for 5 minutes, and further pipetting 10 times.
- a nucleic acid extract was collected with magnetic silica particles collected by a magnet.
- the nucleic acid extraction reagent a mixed solution of 10 mM Tris-HCl (pH 8), 0. ImM ethylenediamine tetraacetic acid (EDTA) (pH 8) and 1 wt% Triton X-100 (trade name) was used.
- Reagents and product names shown in Table 2 below using i-Cycler TM (Bio-Rad Laboratories), heat at 50 ° C for 2 minutes, 95 ° C for 2 minutes, 95 ° C for 10 seconds and 56 ° C Measure the fluorescence intensity in real time while amplifying the extracted nucleic acid by PCR. Set. The number of cycles when the fluorescence intensity reached 100 was measured, and the Ct value (Ctl) of the nucleic acid was determined. The measurement was performed 6 times for each.
- the amounts of reagents shown in Table 2 below are the amounts for the nucleic acid extract 1.
- F-D-NG-Rl-32 (FAM) -ac 11 agagacg 11 acggaaaa t at c aacgag- (DABCYL) (SEQ ID NO: 1) * XG-F3405-20: 5 '-gcggttattttctgctcgct-3' (SEQ ID NO: 2)
- N'G-3526-20R 5 '-accttcgagcagacatcacg-3' (SEQ ID NO: 3)
- the AUGC includes ATP, GTP and CTP (all manufactured by Takara) and UTP (manufactured by Roche).
- the recovery rate of the nucleic acid was calculated from the following equation using the Ct value (Ctl) of the example or comparative example and the Ct value (Ct 2) of the control.
- Ctl Ct value of the example or comparative example
- Ct value (Ct 2) of the control Ct value of the control.
- the obtained Ct values and nucleic acid recovery rates (both average values) are shown in Table 3 below.
- Example 1 2 2 2. 7 25. 7 66
- nucleic acids As shown in Table 4 above, examples using fine particles having a particle diameter of 6 ⁇ m or less and a specific surface area of 50 m 2 / g or less even though the amount of magnetic silica particles is small (1Z10 of Example 1). In (2-1, 2-2 and 2-3), nucleic acids could be recovered with a high recovery rate. On the other hand, in Comparative Example 2 in which fine particles whose particle diameter did not satisfy the above range were used, the recovery of nucleic acid with a very low recovery rate was insufficient. Therefore, it can be said that nucleic acids (bacteria) can be efficiently recovered even with a small amount of magnetic silica particles by using fine particles having a particle size of less than or equal to 50 m 2 / g.
- Example 3 [0059] In this example, cells (gonococci) were collected using a neutral solution containing magnetic silica particles and a salt, and collected cell strength nucleic acids were collected.
- a bacterial cell solution and a microorganism recovery solution were prepared. That is, a total of 6 buffer solutions, 0.5M Tris-HCl buffer solution (pH 7.1) containing 5 kinds of salts (concentration 0.5M) shown in Table 6 below and the above-mentioned buffer solution containing no salt, were used. Got ready. Subsequently, 100 ⁇ L of each buffer solution and 10 L of a magnetic silica-containing solution (400 mgZmL) containing each magnetic silica particle shown in Table 5 below were mixed to prepare the microorganism recovery solution. On the other hand, the bacterial cell solution was prepared by diluting a koji mold suspension (OD: 0.18) prepared in the same manner as in Example 1 100 times with physiological saline.
- OD koji mold suspension
- Example 6 Nucleic acid extraction and PCR were performed in the same manner as in Example 1, Ct value was determined, and nucleic acid recovery rate (%) was calculated. The obtained Ct values and nucleic acid recovery rates are shown in Table 6 below. The values in Table 6 below are average values of 6 measurements, and the values in parentheses are Ct values. The Ct value (Ct2) of the control used to calculate the recovery rate is 24.0 in Example 3-1, and 22.2 in Example 3-2 and Comparative Example 3.
- This example is an example in which a virus solution (HBV) in plasma is collected using a buffer solution containing magnetic silica particles and a protein denaturant, and nucleic acid is collected from the virus cartridge.
- HBV virus solution
- magnetic silica particles having a particle diameter of 0.1 0.4 0.4 111 and a specific surface area of 2 10111 2 78 (manufactured by Band Chemical Co., Ltd .; trade name S—M—03) were used. mL) was prepared. HBV Plasma (ProMedDx “Numberl 0222136”) 1. After adding O / z L to 100 ⁇ L of healthy human plasma, any of the buffer solutions shown in Table 8 below and the magnetic silica particle-containing solution 16 L was added. Then, the virus was adsorbed to the magnetic silica particles by pipetting 30 times, and the supernatant was removed in the same manner as described above.
- nucleic acid extraction reagent 100 L of nucleic acid extraction reagent was added to the washed magnetic silica particles, pipetted 10 times, then heated at 95 ° C for 5 minutes, and further pipetted 10 times to extract the virus power and nucleic acid. In the same manner as described above, the nucleic acid extract was collected to recover the nucleic acid.
- a mixed reagent of 10 mM Tris-HCl (pH 8), 0.1 ImM EDTA (pH 8), and 0.1 weight 0 / oSDS was used as the nucleic acid extraction reagent.
- nucleic acid extract 1.0 / zL
- reagents shown in Table 7 below and brand name i Cycler TM (Bio-Rad Laboratories)
- 50 cycles were performed for 30 seconds at 95 ° C and 60 seconds at 56 ° C, and the number of cycles when the fluorescence intensity was 250 was measured to obtain the Ct value. The measurement was performed three times for each.
- Taqman-BFl-32 (FAM) -caacaaccgacc t tgaggcat ac 11 caaagac- (TAMRA) (Major 4) * IIBV F50-74: 5 '-gaggac tc 11 ggac tctc age aa t g-3' ( (SEQ ID NO: 5)
- Example 4-1 0.5M glycine-HCl (pH 3) 100 57
- Example 4-2 0.5 M glycine-HCl (pH 3) 100 87
- nucleic acid could be recovered at a high recovery rate in any of the Examples.
- the recovery rate was extremely high.
- virus (HBV) in plasma is collected using magnetic silica particles, and nucleic acid is collected from the virus.
- Virus was recovered and nucleic acid was extracted and nucleic acid recovery was calculated in the same manner as in Example 4 except that HC1 buffer (pH 3) was used and fine particles shown in Table 9 below were used. The recovery rate of the resulting nuclear acid is shown in Table 9 below together with the control.
- virus (HBV) in plasma is collected using magnetic silica particles, and nucleic acid is collected from the virus.
- Virus was recovered and nucleic acid was extracted in the same manner as in Example 5 except that 0.5 M glycine-HC1 buffer (PH3) containing 40% ethanol was used as a buffer for microorganism recovery. The nucleic acid recovery rate was calculated. The recovery rate of the obtained nucleic acid is shown in Table 10 below together with the control.
- Example 6-1 0.1 to 0.4 4 to 10 71
- cells (leukocytes) were collected using magnetic silica particles, and nucleic acids were collected from the cells.
- the magnetic silica particles are trade names S— ⁇ -03 (manufactured by Bandichi Kagaku Co., Ltd .: particle diameter 0.1 to 0.4 m, specific surface area 2 to: LOm 2 / g, surface-modified SiO 2). used.
- nucleic acid extraction reagent (Recovery of nucleic acid) Add 50 L of nucleic acid extraction reagent to magnetic silica particles adsorbed with leukocytes, stir with vortex for 5 seconds, heat at 95 ° C for 5 minutes, and further vortex for 5 seconds to remove leukocyte strength. Extracted. A nucleic acid extract was collected in the same manner as described above.
- nucleic acid extraction reagent a mixed reagent of 10 mM Tris-HCl (pH 8), 0. ImM EDTA (pH 8) and 1% Triton X-100 (trade name) was used.
- FIG. 1 is a graph showing changes in fluorescence intensity with increasing PCR cycles. As shown in FIG. 1, in both Examples 7-1 and 7-2, the fluorescence intensity decreased after a certain number of cycles, and thus it was confirmed that nucleic acid was present in the sample. That is, using magnetic silica particles having a particle diameter of 6 m or less and a specific surface area of 50 m 2 Zg or less, leukocytes in blood can be collected and nucleic acids can be collected from the leukocytes.
- Example 2-2 since the fluorescence intensity of Example 2-2 is lower than that of Example 7-1, it can be said that more nucleic acid was detected (recovered) in Example 2-2. That is, collect leukocytes in the blood When using a neutral solution containing MgCl, etc. as a microorganism recovery solution,
- This example is another example in which cells (leukocytes) are collected using magnetic silica particles, and nucleic acids are collected from the cells.
- Example 8-1 is a magnetic silica particle having a particle size of 0.1 to 0.4 ⁇ m and a specific surface area of 2 to 10 m 2 Zg (trade name S—M-05, manufactured by Bandichi Kagaku Co., Ltd.), buffer Contains 1M MgCl as liquid 0
- Example 7 The same procedure as in Example 7 was performed except that heating was performed at 5 ° C for 2 minutes, and 50 cycles were performed at 95 ° C for 15 seconds and 56 ° C for 45 seconds.
- Example 8-2 is a magnetic silica particle having a particle diameter of 2 m and a specific surface area of 2.7 m 2 Zg (trade name)
- Example 8-1 The same procedure as in Example 8-1, except that Micromer (R) — M, manufactured by Micromod Co., Ltd.) was used.
- the particle diameter was 12 / zm and the specific surface area was 0.4.
- FIG. 2 shows the measurement results of real-time PCR in Example 8-1 and Comparative Example 6-1.
- Fig. 3 shows the measurement results of real-time PCR in Example 8-1 and Comparative Example 6-2.
- the particle size is larger than that of Comparative Example 61 using fine particles whose diameter does not satisfy the above range. Was successfully recovered. Further, as shown in FIG.
- Example 8-2 using fine particles having a particle diameter of 6 m or less and a specific surface area of 50 m 2 / g or less, Comparative Example 6 using fine particles having a particle diameter not satisfying the above range was used. More than 2 nucleic acids could be recovered.
- virus was recovered using magnetic silica particles, and the recovered virus force nucleic acid was recovered.
- HCV Plasma (ProMedDx Number9990964) 50 [This buffer solution (0.50 glycine citrate ( ⁇ 3), 40% ethanol) 50 ⁇ L and any one of the above magnetic silica particles] (500 mg / mL) 8 ⁇ L was added and pipetting 30 times to adsorb HCV to the magnetic silica particles. After removing the supernatant in the same manner as described above, 200 ⁇ L of distilled water (Otsuka Pharmaceutical Co., Ltd.) was removed, and the magnetic silica particles adsorbed with HCV were washed by pipetting 10 times. After repeating this washing operation three times, magnetic silica particles were recovered in the same manner as described above.
- a nucleic acid extraction reagent (10 mM Tris-HCl (pH 8), 0.1 ImM EDTA (pH 8) and 0.1 wt. 0 / oSDS) 70 L, RNAsequreagent (Ambion) 5 L and The HCV nucleic acid was extracted by pipetting 10 times, heating at 95 ° C for 5 minutes, and pipetting 10 times.
- 25 ⁇ L of 20% Nodet ⁇ -40 manufactured by Nacalai Testa Co., Ltd. was added, pipetted 10 times, and heated at 60 ° C. for 10 minutes.
- HCV RNA was detected by performing real-time PCR using a target sequence-specific quenching probe, using the reagents shown in Table 15 below, on 5 ⁇ L of the heated nucleic acid extract.
- a target sequence-specific quenching probe using the reagents shown in Table 15 below, on 5 ⁇ L of the heated nucleic acid extract.
- Table 15 the product name i—Cycler TM (Bio—Rad Laboratories) and heating at 60 ° C. for 30 minutes, then 94. Heat at C for 2 minutes, 94. 15 seconds and 60 for C. 60 cycles of 30 seconds at C were performed and heated at 60 ° C for 7 minutes. The results are shown in Fig. 4.
- the reagent marked with ** is a reagent included in the trade name RT—PCR hi h 1 Pl us— “Reverse 1 shot” (TOYOBO CO., LTD).
- Fig. 4 is a graph showing changes in fluorescence intensity with the number of PCR cycles.
- Fig. 4 in the examples (9-1 and 9-2) using fine particles having a particle diameter of 6 ⁇ m or less and a specific surface area of 50 m 2 Zg or less, quenching was observed in an early cycle. It can be said that there is a large amount of collected waste.
- Comparative Example 7 using fine particles whose particle diameter does not satisfy the above range almost no quenching was observed and the recovery rate was low. Therefore, it can be said that viruses can be efficiently recovered by using fine particles with a particle size of 6 m or less and a specific surface area of 50 m 2 Zg or less.
- virus was recovered using magnetic silica particles, and the virus was recovered from the virus. It is the other example which collect
- HCV Plasma (ProMedDx Number9990964) 50 L [This, buffer solution (0.5M glycine—HC1 ( ⁇ 3) and 40% ethanol) 50 ⁇ L, and magnetic silica particles (trade name S— ⁇ —04; band one chemical Co., Ltd., particle size 0.1 to 0.4 111, specific surface area 2-10111 2/8) containing liquid (376MgZmL) 10. added and 64 / z L, magnetic and 30 times pipetting HCV was adsorbed on silica particles. In the same manner as described above, the supernatant was removed, and 100 ⁇ L of distilled water (Otsuka Pharmaceutical) was added, and the magnetic silica particles adsorbed with HCV were washed by pipetting 10 times.
- buffer solution 0.5M glycine—HC1 ( ⁇ 3) and 40% ethanol
- magnetic silica particles (trade name S— ⁇ —04; band one chemical Co., Ltd., particle size 0.1 to 0.4 111, specific surface area 2-10111 2/8) containing liquid (376
- HCV Plasma ProMedDx Number9990964 50 L force HCV RNA was purified, and real-time PCR was performed using a target sequence-specific quenching probe. HCV RNA was detected. The results are shown in FIG. 5 together with Example 10.
- FIG. 5 is a graph showing changes in fluorescence intensity with the number of PCR cycles.
- Example 10 using magnetic silica particles having a particle diameter of 6 ⁇ m or less and a specific surface area of 50 m 2 / g or less is faster than the conventional method using no fine particles (Comparative Example 8).
- the fluorescence was low and the fluorescence intensity was low. Therefore, according to the method of the present invention, it is possible to recover viruses more efficiently than the method without using conventional fine particles.
- This example is still another example in which virus (HIV) is collected using magnetic silica particles, and nucleic acid is collected from the virus.
- virus HIV
- fine particles shown in Table 16 below were prepared.
- HIV Plasma ProMedDx Numberl0439039
- buffer solution 0.5M glycine-chenic acid (pH3), 40% ethanol
- magnetic silica particles listed in Table 16 below Liquid (500mgZ mDS / zL was pipetted and pipetted 30 times to adsorb HIV to the magnetic silica particles.
- the supernatant was removed and distilled water (Otsuka Pharmaceutical) 200
- the magnetic silica particles adsorbed with HIV were washed by pipetting 10 times, and this operation was repeated 3 times, and the supernatant was removed in the same manner as described above, and the nucleic acid extraction reagent (10 mM Tris — Add HCl (pH8), 0.1 ImM EDTA (pH8), 0.1% SDS) 70 L and RNAsequrereagent5 L, pipette 10 times, heat at 95 ° C for 5 minutes, and pipette 10 times HIV nucleic acid was extracted, and 25 ⁇ L of 20% Nodette P-40 ( R ) (manufactured by National Power Tester Co., Ltd.) was added to 75 ⁇ L of the nucleic acid extract. Pipetted 10 times and heated for 10 minutes at 60 ° C. Amplified detection was performed using Amplicor HIV-1 Monitor vl.5 (Roche Diagnostics). 450 nm) is shown
- This example is still another example in which virus (HIV) is collected using magnetic silica particles, and nucleic acid is collected from the virus.
- Nucleic acids were recovered and amplified in the same manner as in Example 11-2. Subsequently, the same procedure as in Example 11-2 was performed, except that dilution series of X1, X1Z5 and X1Z25 were prepared and nucleic acids were detected. The obtained absorbance (450 nm) is shown in Table 17 below.
- HIV recovery ability of Example 11 using the following magnetic silica force particle diameter 6 / zm or less and a specific surface area of 50 m 2 Zg is by Amplicor HIV- 1 Monitor vl. 5 Same or better than pretreatment. Therefore, it can be said that the method for recovering microorganisms of the present invention can recover viruses extremely efficiently.
- This example is an example showing the influence of the specific surface area and particle diameter of fine particles on the recovery rate of microorganisms (cells).
- Example 13-1 Product name s-raQ-oi 1 17. 8 0. 40 12
- Example 13-2 Product name S-FSQ-01 4 14. 7 0. 48 9 Comparative Example 11
- the total surface area is the same, the embodiments using the following and specific surface area of 50 m 2 / g or less of magnetic silica particles having a particle diameter of 6 m (13 1 and 13 In 2), the nucleic acid could be recovered at a higher recovery rate than Comparative Example 11 using magnetic silica particles having a particle diameter exceeding 6 ⁇ m.
- Example 13 3 using the following magnetic silica particles The specific surface area 50 m Zg, than Comparative Example 12 having a specific surface area using magnetic silica particles of more than 50 m 2 / g Nucleic acids could be recovered with a high recovery rate.
- viruses (HBV) and nucleic acids were collected using magnetic silica particles having a constant total surface area of fine particles and different particle sizes. Specifically, virus (HBV) was recovered and nucleic acid was extracted in the same manner as in Example 6 except that the magnetic silica particles shown in Table 20 below were used, and the nucleic acid recovery rate was calculated by PCR. The amount of each fine particle used was adjusted so that its specific surface area (m 2 / g) force was 710 cm 2 in total surface area. The recovery rates obtained are shown in Fig. 8 and Table 20 below.
- virus (HBV) and nucleic acid were collected using magnetic silica particles having a constant fine particle size (1 ⁇ m) and different specific surface areas. Specifically, except that the magnetic silica particles shown in Table 21 below were used and the amount used was 4. Omg, virus (HBV) was recovered and nucleic acid was extracted and PCR was performed in the same manner as in Example 6. The recovery rate of nucleic acid was calculated by The recovery rates obtained are shown in Fig. 9 and Table 21 below.
- microparticles having a particle diameter of 6 ⁇ m or less and a specific surface area of 50 m 2 Zg or less can be efficiently recovered.
- the nucleic acid recovery method of the present invention recovers microorganisms by the microorganism recovery method of the present invention, microorganisms can be efficiently recovered, and as a result, nucleic acids can be efficiently recovered. Therefore, the present invention can be applied to all fields in which microorganisms, nucleic acids, and the like need to be recovered.
- the present invention can be preferably applied to the extraction of components of biological sample strength, but the application is not limited and wide.
- SEQ ID NO: 2 NG-F3405 20 Oligonucleotide probe designed for forward primer
- SEQ ID NO: 3 NG— 3526— 20R oligonucleotide probe designed for reverse primer
- SEQ ID NO: 5 HBV F50—74 oligonucleotide probe designed for the forward primer
- SEQ ID NO: 8 27F1 2 Oligonucleotide probe designed for forward primer
- SEQ ID NO: 9 27R1 2 Oligonucleotide probe designed for reverse primer SEQ ID NO: 10 F— T IAPP— Fl it— 34: Probe
- SEQ ID NO: 14 HC-F303 25— 3a oligonucleotide probe designed for forward primer
- SEQ ID NO: 15 HCV—R402—28 Oligonucleotide probe designed for reverse primer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007516352A JPWO2006123781A1 (ja) | 2005-05-20 | 2006-05-19 | 微粒子を用いた微生物及び核酸の回収方法ならびにそれらに用いるキット |
US11/919,475 US20090311770A1 (en) | 2005-05-20 | 2006-05-19 | Method of collecting microorganisms using fine particles, method of collecting nucleic acids using fine particles, and kits for use in the these methods |
EP06756399A EP1882738A4 (en) | 2005-05-20 | 2006-05-19 | METHOD FOR OBTAINING MICROORGANISMS AND NUCLEIC ACIDS USING FINE PARTICLES AND FOR THE METHOD OF USING THE KIT |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-148256 | 2005-05-20 | ||
JP2005148256 | 2005-05-20 | ||
JP2005222291 | 2005-07-29 | ||
JP2005-222291 | 2005-07-29 | ||
JP2005-362034 | 2005-12-15 | ||
JP2005362034 | 2005-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006123781A1 true WO2006123781A1 (ja) | 2006-11-23 |
Family
ID=37431350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/310043 WO2006123781A1 (ja) | 2005-05-20 | 2006-05-19 | 微粒子を用いた微生物及び核酸の回収方法ならびにそれらに用いるキット |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090311770A1 (ja) |
EP (1) | EP1882738A4 (ja) |
JP (1) | JPWO2006123781A1 (ja) |
WO (1) | WO2006123781A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010034846A1 (es) | 2008-09-26 | 2010-04-01 | Biótica, Bioquímica Analítica, S.L. | Procedimiento rápido de detección de microorganismos con partículas magnéticas |
JP2011155919A (ja) * | 2010-02-02 | 2011-08-18 | Fisheries Research Agency | ノロウイルス検出用材料および該材料を用いるノロウイルスの検出方法 |
KR101349713B1 (ko) | 2012-06-25 | 2014-01-14 | 한국에너지기술연구원 | 아민-자성 나노응집제를 이용한 미세조류의 회수방법 |
KR101443147B1 (ko) | 2013-10-07 | 2014-09-24 | 한국에너지기술연구원 | 아미노클레이가 코팅된 자성물질, 그의 제조방법 및 아미노클레이가 코팅된 자성물질을 이용한 미세조류의 수확방법 |
WO2015098959A1 (ja) * | 2013-12-26 | 2015-07-02 | 国立大学法人名古屋大学 | サンプルの破砕方法、生体分子の抽出方法、及びナノワイヤを含む破砕液 |
JP2017205085A (ja) * | 2016-05-20 | 2017-11-24 | Jnc株式会社 | 磁性粒子を用いた水溶液中の微生物の回収方法および回収装置 |
WO2018062573A1 (ja) * | 2016-09-29 | 2018-04-05 | 栄研化学株式会社 | 細胞の回収方法 |
WO2020117769A1 (en) * | 2018-12-03 | 2020-06-11 | Diagnostics For The Real World, Ltd | Hcv detection |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2443226T3 (pl) * | 2009-06-18 | 2015-04-30 | Merck Patent Gmbh | Sposób izolowania komórek |
CN106659834B (zh) | 2014-08-26 | 2019-06-18 | 3M创新有限公司 | 用于去除血液中的促炎介质以及粒细胞和单核细胞的系统 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62269691A (ja) * | 1986-04-28 | 1987-11-24 | ロ−ム・アンド・ハ−ス・カンパニ− | 細胞培養用又は細胞生産物製造用の微細担体系、及びその製造方法 |
JPS6328392A (ja) * | 1986-07-21 | 1988-02-06 | Fuji Debuison Kagaku Kk | 生体物質固定化担体及びこれを用いる酵母あるいは微生物の固定化法 |
JP2002165591A (ja) * | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
JP2003265164A (ja) * | 2001-05-24 | 2003-09-24 | Kanegafuchi Chem Ind Co Ltd | 力学的刺激負荷が可能な細胞培養装置 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1517758A1 (de) * | 1966-11-02 | 1970-01-29 | Intermag Ag | Verfahren zur mengenbestimmten Fixierung und Dosierung von Mikroorganismen |
JP2965131B2 (ja) * | 1995-07-07 | 1999-10-18 | 東洋紡績株式会社 | 核酸結合用磁性担体およびそれを用いる核酸単離方法 |
DE19851156C1 (de) * | 1998-11-06 | 2000-04-27 | Merck Patent Gmbh | Verfahren zur Isolierung von Plasmid-DNA |
WO2000070040A1 (en) * | 1999-05-14 | 2000-11-23 | Promega Corporation | Cell concentration and lysate clearance using paramagnetic particles |
DE10157624A1 (de) * | 2001-11-26 | 2003-06-05 | Merck Patent Gmbh | Verfahren zur Anreicherung und zum Nachweis von HIV |
-
2006
- 2006-05-19 JP JP2007516352A patent/JPWO2006123781A1/ja not_active Withdrawn
- 2006-05-19 WO PCT/JP2006/310043 patent/WO2006123781A1/ja active Application Filing
- 2006-05-19 EP EP06756399A patent/EP1882738A4/en not_active Withdrawn
- 2006-05-19 US US11/919,475 patent/US20090311770A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62269691A (ja) * | 1986-04-28 | 1987-11-24 | ロ−ム・アンド・ハ−ス・カンパニ− | 細胞培養用又は細胞生産物製造用の微細担体系、及びその製造方法 |
JPS6328392A (ja) * | 1986-07-21 | 1988-02-06 | Fuji Debuison Kagaku Kk | 生体物質固定化担体及びこれを用いる酵母あるいは微生物の固定化法 |
JP2002165591A (ja) * | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
JP2003265164A (ja) * | 2001-05-24 | 2003-09-24 | Kanegafuchi Chem Ind Co Ltd | 力学的刺激負荷が可能な細胞培養装置 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1882738A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010034846A1 (es) | 2008-09-26 | 2010-04-01 | Biótica, Bioquímica Analítica, S.L. | Procedimiento rápido de detección de microorganismos con partículas magnéticas |
JP2011155919A (ja) * | 2010-02-02 | 2011-08-18 | Fisheries Research Agency | ノロウイルス検出用材料および該材料を用いるノロウイルスの検出方法 |
KR101349713B1 (ko) | 2012-06-25 | 2014-01-14 | 한국에너지기술연구원 | 아민-자성 나노응집제를 이용한 미세조류의 회수방법 |
KR101443147B1 (ko) | 2013-10-07 | 2014-09-24 | 한국에너지기술연구원 | 아미노클레이가 코팅된 자성물질, 그의 제조방법 및 아미노클레이가 코팅된 자성물질을 이용한 미세조류의 수확방법 |
WO2015098959A1 (ja) * | 2013-12-26 | 2015-07-02 | 国立大学法人名古屋大学 | サンプルの破砕方法、生体分子の抽出方法、及びナノワイヤを含む破砕液 |
JP2017205085A (ja) * | 2016-05-20 | 2017-11-24 | Jnc株式会社 | 磁性粒子を用いた水溶液中の微生物の回収方法および回収装置 |
WO2018062573A1 (ja) * | 2016-09-29 | 2018-04-05 | 栄研化学株式会社 | 細胞の回収方法 |
WO2020117769A1 (en) * | 2018-12-03 | 2020-06-11 | Diagnostics For The Real World, Ltd | Hcv detection |
Also Published As
Publication number | Publication date |
---|---|
US20090311770A1 (en) | 2009-12-17 |
EP1882738A4 (en) | 2009-02-25 |
JPWO2006123781A1 (ja) | 2008-12-25 |
EP1882738A1 (en) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006123781A1 (ja) | 微粒子を用いた微生物及び核酸の回収方法ならびにそれらに用いるキット | |
JP6364039B2 (ja) | 核酸の単離方法およびキット | |
JP2965131B2 (ja) | 核酸結合用磁性担体およびそれを用いる核酸単離方法 | |
US7329491B2 (en) | Methods for isolating nucleic acids | |
EP1466018A2 (en) | Use of silica material in an amplification reaction | |
WO2016024263A1 (en) | Methods for isolating microbial dna from a blood sample | |
JP2000300262A (ja) | 粒子担体を使用した核酸の抽出方法 | |
EP3347485B1 (en) | Methods for isolating microbial cells from a blood sample | |
US9777264B2 (en) | Materials and method for immobilizing, isolating, and concentrating cells using carboxylated surfaces | |
WO2015159979A1 (ja) | 短鎖核酸の回収方法 | |
JP2003235555A (ja) | 一本鎖核酸および/または二本鎖核酸の単離方法 | |
JP4214255B2 (ja) | 粒子担体を使用する改良された核酸の抽出方法 | |
EP2171098B1 (en) | Methods for extraction and purification of components of biological samples | |
JP5543694B2 (ja) | 生体関連物質の分離回収方法 | |
EP1524317B1 (en) | Methods for isolating nucleic acids | |
JP2001139593A (ja) | 粒子担体を使用する改良された核酸の抽出方法 | |
JP2001078761A (ja) | 核酸結合性磁性シリカ粒子担体 | |
JP2013226149A (ja) | 生体関連物質の分離回収方法 | |
JP2004286749A (ja) | アッセイサンプルを調製するための方法 | |
CN101180392A (zh) | 使用了微粒的微生物和核酸的回收方法以及该方法中使用的试剂盒 | |
US20220064695A1 (en) | Methods for isolating microbial cells from a blood sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680017523.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007516352 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11919475 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006756399 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006756399 Country of ref document: EP |